

## Supplementary Online Content

Arnold SV, Chinnakondepalli KM, Magnuson EA, et al; CoreValve US Pivotal Trial Investigators. Five-year health status after self-expanding transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis *JAMA Cardiol*. Published online September 30, 2020. doi:10.1001/jamacardio.2020.4397

**eTable 1.** Baseline characteristics stratified by access site

**eTable 2.** Unadjusted mean ( $\pm$  SD) health status scores over time and within group comparisons to baseline

**eTable 3.** Between group differences in health status, stratified by access site

**eTable 4.** Predicted mean values and between group comparisons of KCCQ-OS, according to pattern mixture models (Iliofemoral cohort)

This supplementary material has been provided by the authors to give readers additional information about their work.

<b>eTable 1. Baseline characteristics stratified by access site</b>						
	<b>Iliofemoral</b>			<b>Non-Iliofemoral</b>		
	<b>TAVR (N=316)</b>	<b>SAVR (N=283)</b>	<b>P-Value</b>	<b>TAVR (N=61)</b>	<b>SAVR (N=53)</b>	<b>P-Value</b>
Age, years	83.5 ± 6.9	83.5 ± 6.3	0.901	81.9 ± 8.1	83.4 ± 6.5	0.282
Male sex	168 (53.2%)	151 (53.4%)	0.962	31 (50.8%)	27 (50.9%)	0.989
STS Risk Score, %	7.3 ± 3.1	7.6 ± 3.2	0.331	7.2 ± 2.6	7.7 ± 4.1	0.465
Prior Myocardial Infarction	70 (22.2%)	67 (23.7%)	0.657	23 (37.7%)	15 (28.3%)	0.288
Prior Coronary Artery Bypass Surgery	97 (30.7%)	88 (31.1%)	0.915	13 (21.3%)	18 (34.0%)	0.130
Prior Percutaneous Coronary Intervention	105 (33.2%)	108 (38.2%)	0.207	27 (44.3%)	20 (37.7%)	0.480
Prior Pacemaker	76 (24.1%)	63 (22.3%)	0.604	10 (16.4%)	9 (17.0%)	0.933
Prior Stroke	54 (17.1%)	54 (19.1%)	0.526	9 (14.8%)	17 (32.7%)	0.023
Peripheral Vascular Disease	115 (36.7%)	104 (37.0%)	0.945	38 (62.3%)	36 (67.9%)	0.529
Chronic Lung Disease	142 (44.9%)	132 (46.6%)	0.675	27 (44.3%)	18 (34.0%)	0.261
Home Oxygen	43 (13.7%)	33 (11.7%)	0.465	5 (8.2%)	3 (5.7%)	0.722
Diabetes Mellitus	104 (32.9%)	125 (44.2%)	0.004	24 (39.3%)	21 (39.6%)	0.975
Atrial Fibrillation	130 (41.1%)	139 (49.1%)	0.050	25 (41.7%)	21 (39.6%)	0.825
Chronic Kidney Disease						
Stage III	189 (59.8%)	170 (60.1%)	0.948	35 (57.4%)	32 (60.4%)	0.745
Stage IV/V	33 (10.4%)	30 (10.6%)	0.949	9 (14.8%)	7 (13.2%)	0.812
Ejection Fraction, %	58.0 ± 11.1	57.3 ± 11.7	0.484	57.1 ± 13.6	58.6 ± 12.6	0.562
Mean Aortic Gradient, mmHg	48.5 ± 15.3	47.9 ± 14.4	0.621	46.7 ± 16.5	46.5 ± 11.8	0.943
KCCQ Overall Summary Score	45.9 ± 23.5	45.9 ± 22.4	0.983	51.5 ± 22.1	51.2 ± 21.0	0.937
KCCQ Physical Limitations	45.6 ± 25.2	45.7 ± 25.0	0.992	50.9 ± 22.9	47.9 ± 24.9	0.500
KCCQ Total Symptoms	55.4 ± 24.9	54.4 ± 24.6	0.599	59.9 ± 22.4	61.2 ± 23.6	0.768
KCCQ Quality of Life	40.6 ± 24.8	41.8 ± 23.6	0.535	45.9 ± 24.7	45.1 ± 23.8	0.864
KCCQ Social Limitations	40.6 ± 30.3	40.3 ± 29.6	0.906	48.5 ± 30.9	49.4 ± 28.0	0.872
SF-12 Physical Summary Score	30.6 ± 9.0	30.6 ± 8.4	0.927	31.4 ± 10.1	32.8 ± 9.0	0.437
SF-12 Mental Summary Score	47.0 ± 12.3	48.7 ± 11.6	0.098	49.5 ± 10.5	46.8 ± 11.7	0.197

<b>eTable 2. Unadjusted mean (<math>\pm</math> SD) health status scores over time and within group comparisons to baseline</b>								
	<b>Iliofemoral</b>				<b>Non-Iliofemoral</b>			
<b>Scale/Time Point</b>	<b>TAVR (n=331)</b>	<b>p-value</b>	<b>SAVR (n=334)</b>	<b>p-value</b>	<b>TAVR (n=64)</b>	<b>p-value</b>	<b>SAVR (n=68)</b>	<b>p-value</b>
<b>KCCQ Overall Summary</b>								
Baseline	45.9 $\pm$ 23.5		45.9 $\pm$ 22.4		51.5 $\pm$ 22.1		51.2 $\pm$ 21.0	
1 month	67.7 $\pm$ 23.4	<0.001	51.1 $\pm$ 24.7	0.073	57.1 $\pm$ 26.2	0.529	55.5 $\pm$ 29.2	0.348
6 months	72.3 $\pm$ 21.9	<0.001	71.0 $\pm$ 21.1	<0.001	72.1 $\pm$ 24.9	<0.001	68.8 $\pm$ 25.8	0.001
1 year	72.4 $\pm$ 21.4	<0.001	69.6 $\pm$ 22.2	<0.001	69.5 $\pm$ 24.2	<0.001	77.0 $\pm$ 20.4	<0.001
2 years	72.3 $\pm$ 21.9	<0.001	66.5 $\pm$ 23.1	<0.001	68.4 $\pm$ 24.7	0.006	68.8 $\pm$ 25.2	0.004
3 years	66.6 $\pm$ 23.9	<0.001	70.0 $\pm$ 21.7	<0.001	70.4 $\pm$ 22.3	0.058	69.8 $\pm$ 23.7	0.013
4 years	68.2 $\pm$ 24.3	<0.001	67.7 $\pm$ 21.7	<0.001	68.6 $\pm$ 23.7	0.014	69.4 $\pm$ 19.4	0.032
5 years	65.7 $\pm$ 20.5	<0.001	65.3 $\pm$ 21.3	<0.001	71.1 $\pm$ 25.0	0.047	70.1 $\pm$ 14.0	0.031
<b>KCCQ Physical Limitations</b>								
Baseline	45.6 $\pm$ 25.2		45.7 $\pm$ 25.0		50.9 $\pm$ 22.9		47.9 $\pm$ 24.9	
1 month	61.6 $\pm$ 27.7	<0.001	45.5 $\pm$ 27.8	0.414	52.1 $\pm$ 31.2	0.476	49.5 $\pm$ 31.6	0.620
6 months	62.5 $\pm$ 26.0	<0.001	62.3 $\pm$ 25.6	<0.001	61.7 $\pm$ 33.4	0.047	60.8 $\pm$ 27.6	0.009
1 year	62.9 $\pm$ 26.8	<0.001	60.0 $\pm$ 25.9	<0.001	59.7 $\pm$ 29.3	0.051	64.0 $\pm$ 27.2	0.001
2 years	59.9 $\pm$ 26.5	<0.001	56.7 $\pm$ 26.1	0.005	55.5 $\pm$ 30.3	0.758	58.1 $\pm$ 29.8	0.091
3 years	54.5 $\pm$ 28.1	0.065	59.1 $\pm$ 26.0	0.002	57.7 $\pm$ 26.3	0.738	60.3 $\pm$ 27.9	0.191
4 years	54.5 $\pm$ 25.6	0.118	57.2 $\pm$ 24.9	0.065	56.5 $\pm$ 29.9	0.382	57.0 $\pm$ 26.9	0.625
5 years	54.8 $\pm$ 24.8	0.428	53.5 $\pm$ 23.5	0.391	62.1 $\pm$ 31.0	0.251	61.1 $\pm$ 21.7	0.200
<b>KCCQ Total Symptoms</b>								
Baseline	55.4 $\pm$ 24.9		54.4 $\pm$ 24.6		59.9 $\pm$ 22.4		61.2 $\pm$ 23.6	
1 month	72.5 $\pm$ 21.4	<0.001	62.0 $\pm$ 24.2	0.016	65.4 $\pm$ 23.7	0.500	65.9 $\pm$ 25.1	0.490
6 months	77.2 $\pm$ 20.8	<0.001	77.1 $\pm$ 19.6	<0.001	77.6 $\pm$ 20.5	<0.001	76.0 $\pm$ 25.8	0.033
1 year	75.7 $\pm$ 21.0	<0.001	74.6 $\pm$ 22.0	<0.001	73.8 $\pm$ 22.4	0.002	82.4 $\pm$ 19.4	<0.001
2 years	76.9 $\pm$ 21.3	<0.001	71.7 $\pm$ 23.5	<0.001	73.7 $\pm$ 22.5	0.034	74.5 $\pm$ 22.0	0.036
3 years	71.6 $\pm$ 22.3	<0.001	75.5 $\pm$ 21.2	<0.001	73.9 $\pm$ 20.3	0.209	77.3 $\pm$ 20.8	0.030
4 years	73.5 $\pm$ 23.2	<0.001	73.6 $\pm$ 21.3	<0.001	76.8 $\pm$ 23.7	0.043	79.2 $\pm$ 14.9	0.061
5 years	70.1 $\pm$ 21.6	0.017	69.3 $\pm$ 21.4	0.000	75.0 $\pm$ 23.6	0.137	77.8 $\pm$ 12.0	0.105
<b>KCCQ Quality of Life</b>								
Baseline	40.6 $\pm$ 24.8		41.8 $\pm$ 23.6		45.9 $\pm$ 24.7		45.1 $\pm$ 23.8	
1 month	71.0 $\pm$ 26.1	<0.001	52.1 $\pm$ 27.6	<0.001	59.6 $\pm$ 30.8	0.052	53.4 $\pm$ 31.3	0.088
6 months	77.2 $\pm$ 24.3	<0.001	73.8 $\pm$ 25.7	<0.001	75.8 $\pm$ 23.7	<0.001	67.4 $\pm$ 27.0	<0.001
1 year	77.1 $\pm$ 23.4	<0.001	75.9 $\pm$ 23.6	<0.001	71.2 $\pm$ 26.1	<0.001	79.8 $\pm$ 21.0	<0.001
2 years	78.9 $\pm$ 22.7	<0.001	72.7 $\pm$ 24.5	<0.001	72.9 $\pm$ 25.8	<0.001	70.0 $\pm$ 26.2	<0.001
3 years	74.9 $\pm$ 25.4	<0.001	76.7 $\pm$ 22.5	<0.001	76.0 $\pm$ 22.9	0.001	70.6 $\pm$ 26.8	0.001
4 years	75.2 $\pm$ 26.1	<0.001	74.9 $\pm$ 22.9	<0.001	72.1 $\pm$ 23.1	<0.001	72.6 $\pm$ 22.1	0.001
5 years	74.5 $\pm$ 21.8	<0.001	70.8 $\pm$ 24.3	<0.001	78.3 $\pm$ 22.9	0.001	71.2 $\pm$ 17.9	0.016

Scale/Time Point	Iliofemoral				Non-Iliofemoral			
	TAVR (n=331)	p-value	SAVR (n=334)	p-value	TAVR (n=64)	p-value	SAVR (n=68)	p-value
<b>KCCQ Social Limitation</b>								
Baseline	40.6 ± 30.3		40.3 ± 29.6		48.5 ± 30.9		49.4 ± 28.0	
1 month	61.6 ± 30.3	<0.001	43.3 ± 31.7	0.895	46.1 ± 32.0	0.550	43.0 ± 35.7	0.932
6 months	68.6 ± 29.7	<0.001	67.9 ± 26.5	<0.001	71.3 ± 31.2	0.003	65.7 ± 34.1	0.148
1 year	71.0 ± 28.6	<0.001	66.5 ± 29.2	<0.001	70.2 ± 28.2	<0.001	78.6 ± 25.2	0.003
2 years	70.2 ± 29.6	<0.001	62.4 ± 29.9	<0.001	69.1 ± 29.5	0.008	67.6 ± 31.5	0.092
3 years	61.1 ± 30.9	<0.001	64.6 ± 29.7	<0.001	74.1 ± 32.6	0.220	68.3 ± 28.6	0.075
4 years	58.6 ± 33.1	<0.001	61.3 ± 30.2	<0.001	65.6 ± 29.5	0.093	66.4 ± 27.6	0.422
5 years	61.2 ± 29.9	0.014	62.9 ± 27.4	<0.001	64.4 ± 30.8	0.189	72.2 ± 18.4	0.135
<b>SF-12 Physical Summary</b>								
Baseline	30.6 ± 9.0		30.6 ± 8.4		31.4 ± 10.1		32.8 ± 9.0	
1 month	36.3 ± 9.6	<0.001	31.7 ± 8.6	0.889	33.3 ± 9.7	0.412	33.2 ± 9.1	0.667
6 months	37.2 ± 10.3	<0.001	37.6 ± 9.7	<0.001	38.4 ± 10.4	0.002	37.9 ± 11.9	0.082
1 year	36.7 ± 11.4	<0.001	36.4 ± 9.7	<0.001	38.9 ± 9.7	0.003	39.6 ± 9.3	0.004
2 years	36.1 ± 10.7	<0.001	34.9 ± 10.1	<0.001	36.4 ± 11.8	0.120	39.4 ± 8.8	0.027
3 years	34.4 ± 10.8	0.001	35.9 ± 9.7	<0.001	35.2 ± 12.4	0.549	36.8 ± 10.6	0.557
4 years	34.6 ± 10.8	0.001	35.0 ± 9.4	0.001	33.4 ± 10.6	0.582	35.8 ± 9.0	0.783
5 years	32.5 ± 10.8	0.498	33.2 ± 8.8	0.181	34.0 ± 11.0	0.921	33.1 ± 8.2	0.332
<b>SF-12 Mental Summary</b>								
Baseline	47.0 ± 12.3		48.7 ± 11.6		49.5 ± 10.5		46.8 ± 11.7	
1 month	51.4 ± 10.9	<0.001	44.7 ± 12.7	0.010	48.8 ± 12.6	0.278	47.3 ± 15.3	0.900
6 months	52.6 ± 10.7	<0.001	51.4 ± 11.0	0.011	51.8 ± 11.7	0.319	49.7 ± 10.4	0.318
1 year	52.7 ± 10.6	<0.001	52.5 ± 10.8	0.004	52.7 ± 12.2	0.098	53.0 ± 8.7	0.058
2 years	51.8 ± 11.2	<0.001	50.7 ± 11.3	0.137	52.2 ± 10.6	0.355	48.5 ± 10.0	0.619
3 years	51.8 ± 11.8	0.003	52.7 ± 10.2	0.012	53.4 ± 10.6	0.493	50.6 ± 10.7	0.220
4 years	51.7 ± 11.6	0.030	50.9 ± 10.0	0.241	54.1 ± 7.3	0.288	47.7 ± 11.0	0.758
5 years	50.5 ± 10.7	0.755	50.2 ± 11.2	0.418	50.0 ± 11.8	0.941	52.3 ± 11.4	0.361

<b>eTable 3. Between group differences in health status, stratified by access site</b>				
	<b>Iliofemoral</b>		<b>Non-Iliofemoral</b>	
	<b>Mean Treatment Difference (TAVR-SAVR) (95% CI)</b>	<b>P-Value</b>	<b>Mean Treatment Difference (TAVR-SAVR) (95% CI)</b>	<b>P-Value</b>
<b>KCCQ Overall Summary</b>				
1 Month	16.8 (12.4 to 21.2)	<0.001	-0.8 (-11.6 to 9.9)	0.880
6 Months	1.8 (-2.4 to 6.1)	0.395	0.0 (-10.0 to 10.0)	0.999
1 Year	2.4 (-2.0 to 6.8)	0.280	-1.5 (-12.0 to 9.1)	0.786
2 Years	4.0 (-0.5 to 8.6)	0.084	-1.0 (-12.3 to 10.3)	0.865
3 Years	-2.5 (-7.5 to 2.5)	0.327	0.4 (-11.6 to 12.3)	0.951
4 Years	2.5 (-2.8 to 7.8)	0.357	2.8 (-9.5 to 15.1)	0.658
5 Years	1.7 (-4.2 to 7.7)	0.566	2.3 (-11.6 to 16.1)	0.748
<b>KCCQ Physical Limitations</b>				
1 Month	17.1 (11.8 to 22.5)	<0.001	-1.7 (-14.8 to 11.5)	0.804
6 Months	1.2 (-3.9 to 6.3)	0.648	-3.8 (-15.7 to 8.0)	0.525
1 Year	1.6 (-3.6 to 6.8)	0.550	-1.6 (-14.0 to 10.9)	0.803
2 Years	3.1 (-2.4 to 8.5)	0.269	-6.4 (-20.0 to 7.2)	0.358
3 Years	-3.9 (-9.8 to 2.1)	0.200	-6.5 (-20.6 to 7.7)	0.370
4 Years	1.1 (-5.3 to 7.5)	0.737	0.3 (-14.4 to 15.1)	0.966
5 Years	4.3 (-2.8 to 11.3)	0.233	-4.4 (-20.7 to 12.0)	0.602
<b>KCCQ Total Symptoms</b>				
1 Month	10.1 (5.9 to 14.3)	<0.001	-1.9 (-12.2 to 8.4)	0.724
6 Months	0.4 (-3.6 to 4.5)	0.835	1.4 (-8.1 to 10.9)	0.766
1 Year	1.0 (-3.2 to 5.2)	0.634	-4.8 (-14.9 to 5.3)	0.350
2 Years	3.6 (-0.8 to 8.0)	0.111	-1.9 (-12.8 to 9.0)	0.732
3 Years	-3.3 (-8.2 to 1.5)	0.178	-3.5 (-15.1 to 8.1)	0.559
4 Years	1.3 (-3.9 to 6.5)	0.617	2.4 (-9.6 to 14.4)	0.694
5 Years	1.2 (-4.7 to 7.0)	0.701	-0.9 (-14.5 to 12.8)	0.898
<b>KCCQ Quality of Life</b>				
1 Month	19.6 (14.7 to 24.5)	<0.001	3.3 (-8.7 to 15.2)	0.590
6 Months	4.2 (-0.5 to 9.0)	0.081	3.1 (-8.1 to 14.3)	0.588
1 Year	1.3 (-3.6 to 6.2)	0.600	-3.9 (-15.8 to 7.9)	0.513
2 Years	4.9 (-0.2 to 10.1)	0.058	2.3 (-10.4 to 14.9)	0.726
3 Years	-1.1 (-6.7 to 4.5)	0.698	2.4 (-11.1 to 15.8)	0.729
4 Years	1.5 (-4.4 to 7.5)	0.615	2.6 (-11.1 to 16.4)	0.709
5 Years	5.1 (-1.7 to 11.9)	0.141	8.1 (-7.7 to 23.8)	0.316

	<b>Iliofemoral</b>		<b>Non-Iliofemoral</b>	
	<b>Mean Treatment Difference (TAVR-SAVR) (95% CI)</b>	<b>P-Value</b>	<b>Mean Treatment Difference (TAVR-SAVR) (95% CI)</b>	<b>P-Value</b>
<b>KCCQ Social Limitation</b>				
1 Month	18.7 (12.4 to 25.1)	<0.001	-3.0 (-19.3 to 13.4)	0.722
6 Months	1.4 (-4.7 to 7.4)	0.654	6.3 (-7.9 to 20.4)	0.384
1 Year	1.4 (-4.8 to 7.6)	0.660	5.1 (-9.6 to 19.9)	0.493
2 Years	2.0 (-4.6 to 8.6)	0.550	0.6 (-14.9 to 16.1)	0.941
3 Years	-4.3 (-11.4 to 2.8)	0.232	5.6 (-11.3 to 22.5)	0.515
4 Years	-1.7 (-9.3 to 6.0)	0.672	7.3 (-9.8 to 24.4)	0.403
5 Years	-2.1 (-10.9 to 6.7)	0.642	-2.6 (-23.2 to 18.1)	0.807
<b>SF-12 Physical Summary</b>				
1 Month	4.9 (3.0 to 6.9)	<0.001	2.5 (-2.4 to 7.4)	0.325
6 Months	-0.6 (-2.5 to 1.3)	0.539	1.5 (-2.8 to 5.8)	0.496
1 Year	0.4 (-1.5 to 2.4)	0.653	0.7 (-3.9 to 5.4)	0.753
2 Years	0.7 (-1.3 to 2.8)	0.483	-2.4 (-7.4 to 2.6)	0.344
3 Years	-1.5 (-3.7 to 0.7)	0.192	-0.3 (-5.5 to 5.0)	0.920
4 Years	0.6 (-1.7 to 3.0)	0.603	0.6 (-4.9 to 6.1)	0.833
5 Years	-0.3 (-3.0 to 2.4)	0.801	0.9 (-5.6 to 7.3)	0.796
<b>SF-12 Mental Summary</b>				
1 Month	6.6 (4.3 to 8.8)	<0.001	-1.7 (-7.2 to 3.9)	0.560
6 Months	2.0 (-0.1 to 4.1)	0.063	-0.2 (-5.1 to 4.7)	0.938
1 Year	1.1 (-1.1 to 3.3)	0.332	0.9 (-4.3 to 6.2)	0.726
2 Years	1.0 (-1.4 to 3.3)	0.423	2.3 (-3.4 to 8.0)	0.428
3 Years	-0.3 (-2.9 to 2.2)	0.807	1.8 (-4.2 to 7.8)	0.553
4 Years	1.0 (-1.7 to 3.7)	0.471	7.1 (0.8 to 13.5)	0.027
5 Years	0.0 (-3.1 to 3.1)	0.985	-1.2 (-8.7 to 6.3)	0.753

**eTable 4. Predicted mean values and between group comparisons of KCCQ-OS, according to pattern mixture models (Iliofemoral cohort)**

	<b>TAVR</b>	<b>SAVR</b>	<b>Mean Treatment Difference (TAVR-SAVR) (95% CI)</b>	<b>P-Value</b>
1 Month	67.2 (64.8-69.6)	57.6 (54.8-60.3)	9.6 (6.1 to 13.2)	<0.001
6 Months	69.9 (67.8-72.0)	62.9 (60.6-65.2)	7.0 (3.9 to 10.1)	<0.001
1 Year	71.1 (69.0-73.2)	66.7 (64.3-69.0)	4.4 (1.4 to 7.4)	0.004
2 Years	68.4 (66.2-70.7)	67.4 (64.8-70.0)	1.0 (-2.3 to 4.4)	0.546
3 Years	62.3 (59.7-64.9)	62.3 (59.2-65.3)	0.0 (-3.9 to 4.0)	0.981
4 Years	56.5 (52.7-60.3)	55.1 (50.8-59.3)	1.4 (-3.7 to 6.5)	0.579
5 Years	54.8 (47.2-62.4)	49.6 (41.5-57.7)	5.2 (-2.5 to 13.0)	0.185